Lercanidipine
From Self-sufficiency
| File:Lercanidipine.svg | |
| Systematic (IUPAC) name | |
|---|---|
|
2[(3,3-diphenylpropyl)(methyl)amino]-1,1-dimethylethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate | |
| Identifiers | |
| CAS Number | 100427-26-7 |
| ATC code | C08CA13 (WHO) |
| PubChem | CID 65866 |
| DrugBank | APRD00193 |
| Chemical data | |
| Formula | C36H41N3O6 |
| Molar mass | 611.727 g/mol[[Script error: No such module "String".]] |
| (verify) | |
Lercanidipine is a calcium channel blocker of the dihydropyridine class.
It is sold under various commercial names including Zanidip.
Further reading
- Lin T, Voon W, Yen H, Huang C, Su H, Lai W, Sheu S (2006). "Lercanidipine and losartan effects on blood pressure and fibrinolytic parameters". Kaohsiung J Med Sci. 22 (4): 177–83. doi:10.1016/S1607-551X(09)70304-3. PMID 16679299.
- Martinez M, Lopes L, Coelho E, Nobre F, Rocha J, Gerlach R, Tanus-Santos J (2006). "Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension". J Cardiovasc Pharmacol. 47 (1): 117–22. doi:10.1097/01.fjc.0000196241.96759.71. PMID 16424795.
- Agrawal R, Marx A, Haller H (2006). "Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension". J Hypertens. 24 (1): 185–92. doi:10.1097/01.hjh.0000198987.34588.11. PMID 16331117.
External links
| 30px | This drug article relating to the cardiovascular system is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- CS1 maint: Multiple names: authors list
- Calcium channel blockers
- Pyridines
- Carboxylate esters
- Nitro compounds
- Amines
- Cardiovascular system drug stubs
- 2Fix
